Lead Product(s) : STRO-002,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 21, 2022
Lead Product(s) : STRO-002,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : STRO-002
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Tianjin Tasly Group
Deal Size : $385.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Tasly will pursue the clinical development, regulatory approval, and commercialization of STRO-002 in Greater China for ovarian and endometrial cancers.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : $40.0 million
December 27, 2021
Lead Product(s) : STRO-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Tianjin Tasly Group
Deal Size : $385.0 million
Deal Type : Licensing Agreement
Details : STRO-002 is an internally developed, folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for the potential treatment of ovarian cancer.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 21, 2021
Details : STRO-002 continues to be well-tolerated and 86% of all treatment-emergent adverse events (AEs) were Grade 1 or 2. Of note, prophylactic corticosteroid eye drops have not been required and no ocular toxicity signals have been observed.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 03, 2020
Details : STRO-002-GM1, the Phase 1 open-label, multicenter, dose escalation trial with dose expansion of STRO-002, has completed enrollment. STRO-002 is a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC).
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 24, 2020
Details : EDT to discuss updated data from the company’s ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate (ADC), STRO-002, in ovarian and endometrial cancer.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 02, 2020
Lead Product(s) : STRO-002,Avelumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company announced preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, demonstrating it’s immune-modulating properties and potentiation by PD-L1 blockade.
Brand Name : STRO-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 22, 2020
Lead Product(s) : STRO-002,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate
Details : Company will present new preclinical data for its folate receptor alpha targeting antibody-drug conjugate, STRO-002, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 09, 2020
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate
Details : The AACR presentation will include updated initial dose escalation safety and efficacy data from the company's ongoing Phase I study of STRO-002 in ovarian and endometrial cancer.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 13, 2020
LOOKING FOR A SUPPLIER?
Reset All
